Difference between revisions of "Regimen classes"
Jump to navigation
Jump to search
m |
|||
| Line 6: | Line 6: | ||
=Anti-CD20-based regimen= | =Anti-CD20-based regimen= | ||
==Rituximab-containing regimen== | ==Rituximab-containing regimen== | ||
| + | |||
| + | =Anti-HER2-based regimen= | ||
| + | ==Trastuzumab-based regimen== | ||
=Anti-VEGF biologic therapy= | =Anti-VEGF biologic therapy= | ||
| Line 28: | Line 31: | ||
==Single-agent immunotherapy== | ==Single-agent immunotherapy== | ||
=Taxane-based regimen= | =Taxane-based regimen= | ||
| − | |||
=Tyrosine kinase inhibitor therapy= | =Tyrosine kinase inhibitor therapy= | ||
Revision as of 22:56, 26 February 2020
The purpose of this page is to define regimen classes that will be used in the HemOnc vocabulary; it is not for other purposes at this time.